Zappy Health Review: What Its GLP-1 Documentation Establishes—and What It Does Not

A telehealth company can document a prescription service without documenting how well its own patients do. That distinction is central to evaluating Zappy Health. Its public pages describe online intake, independent prescribing professionals, outside pharmacies and several payment tracks for weight-management medication. They do not establish that outcomes from major drug trials are outcomes of Zappy’s service. The more immediate evidence question is whether a prospective patient can identify the exact product, responsible pharmacy, included care and applicable payment terms before enrolling.

This review examines public documentation consulted October 19, 2026, separating Zappy’s commercial descriptions from clinical and regulatory context. The company provides considerable practical detail, including published prices and contact routes. However, different pages offer conflicting accounts of cancellation, shipment timing and pharmacy arrangements. Those differences do not establish that care is ineffective or unavailable. They do mean that a polished product page is not enough to resolve what a particular patient would receive, pay or be entitled to cancel.

At a glance

Business and clinical responsibility: Kare Solutions, LLC does business as Zappy Health. Its terms describe a technology platform connecting patients with independent clinicians and third-party pharmacies, not a company practicing medicine itself.
Sources: [9]
Two different payment models: The help center distinguishes medication-inclusive, cash-pay compounded plans from a $99/month brand-name care membership with medication billed separately by the pharmacy.
Sources: [6]
Published monthly compounded prices: Compounded semaglutide is advertised at $249/month, billed monthly; compounded tirzepatide is advertised at $349/month, billed monthly. Prepaid and introductory packages have separate conditions.
Sources: [8] [10]
Compounded-product limitation: Zappy acknowledges that compounded medicines are not FDA approved. FDA recommends compounding when an individual’s medical needs cannot be met by an approved drug; nonapproval alone does not establish clinical inequivalence.
Sources: [13] [1]
Unresolved cancellation terms: Public pages combine cancel-anytime language, shipment-dependent refund restrictions and a FAQ describing a two-month commitment after prescription and shipment. The applicable rule needs written clarification.
Sources: [14] [5] [12]

Start with the service being documented

Zappy’s terms identify its operator as Kare Solutions, LLC, doing business as Zappy Health. They assign different responsibilities to the platform, independent licensed healthcare providers and partner pharmacies. Zappy facilitates communication and prescription fulfillment; the terms say it does not itself provide medical, diagnostic or pharmaceutical services. Clinical decisions belong to the independent professionals, and a prescription is not guaranteed. This is a meaningful allocation of responsibility, not simply a branding detail: the company collecting payment is not necessarily the entity making a treatment decision.

The documented catalog includes compounded semaglutide and compounded tirzepatide, alongside brand-name injectable and oral options. The semaglutide page describes a once-weekly injection for eligible patients. The tirzepatide page makes compounded prescribing conditional on individual evaluation and availability. Neither description establishes that every applicant can obtain either product. The consulted material also does not identify the clinical contracting entity or the individual professional who would treat a particular patient, and this review did not independently verify professional licenses.

Those limits define the value of public provider documentation: it can establish advertised services and published responsibilities, but not independently confirm every operational claim. Before payment, a useful documentary request is the name and credential of the treating professional, the clinical entity responsible for care and the dispensing pharmacy for the proposed prescription. Those answers would turn a general platform description into a more specific account of the patient’s actual service.

Sources: [9] [13] [10]

Product evidence is not evidence of Zappy’s results

Zappy explicitly acknowledges that compounded medicines are not FDA approved and have not been evaluated by FDA for safety, effectiveness or quality. FDA’s guidance adds an important distinction: compounded preparations do not undergo the agency’s premarket review, and FDA recommends them when an individual’s medical needs cannot be met by an approved medicine. That recommendation should inform the prescribing discussion; it is not a basis for declaring every compounded prescription categorically unlawful or every compounded preparation clinically inequivalent.

The major semaglutide and tirzepatide studies answer narrower questions than a provider advertisement might suggest. STEP 1 and SURMOUNT-1 studied specified subcutaneous regimens in adults without diabetes over defined periods. They were not studies of Zappy’s service or its compounded products. STEP 1 was funded by Novo Nordisk; SURMOUNT-1 was funded by Eli Lilly. Their results cannot simply be transferred to other routes, formulations or an individual patient, and comparing separate trials does not establish a head-to-head ranking.

For this review, the crucial distinction is between an ingredient’s research history and evidence for the exact preparation being offered. The consulted documentation does not supply provider-specific outcome data that bridge that gap. Our explanation of approved medicines and compounded preparations addresses these separate questions. Approval attaches to a specific product—not to a telehealth platform or pharmacy—and the absence of approval alone neither validates nor condemns the entire service.

Sources: [13] [1] [3] [4]

What the advertised prices actually include

Zappy’s help center makes a useful distinction between two payment structures. Cash-pay compounded plans include the medication, while the brand-name track charges $99/month for healthcare services and bills medication separately at the pharmacy. A general pricing FAQ saying medicines are separate does not neatly explain the compounded offer. The clearest reading is therefore product-specific, rather than assuming one rule covers the catalog. Monthly billing is an alternative to prepaid packages, not a requirement to purchase several months upfront.

For compounded injectable semaglutide, the published standard price is $249/month. A three-month package costs $687 upfront, displayed as $229/month; the product page also lists six months for $1,254 upfront, displayed as $209/month. The first-time GLP-1 starter package costs $477 upfront for three months, displayed as $159/month. That starter offer is unavailable in Alabama, Arkansas, California, Kansas, Michigan, Minnesota and Mississippi. Its introductory eligibility should not be confused with the standard monthly price.

Compounded tirzepatide is listed at $349/month, or $987 upfront for three months and $1,794 upfront for six months. Its first-time GLP-1 starter package is $837 upfront for three months, displayed as $279/month; the help center places these offers under a “For Most States” heading. Multi-month packages may not accept additional promotions. These package durations do not, by themselves, establish how many vials arrive at once, and the public material does not clearly establish a starter package’s subsequent price.

Published payment examples: monthly equivalents are not always monthly charges
Offering	Published payment	Important condition
Compounded injectable semaglutide, standard	$249/month	Billed monthly; medication included
Compounded semaglutide starter package	$477 upfront for three months; displayed as $159/month	First-time GLP-1 users; seven named states excluded
Compounded tirzepatide, standard	$349/month	Billed monthly; medication-inclusive compounded track
Compounded tirzepatide, six-month package	$1,794 upfront; displayed as $299/month	Prepaid package; shipment schedule requires confirmation
Brand-name medication track	$99/month for care	Medication billed separately at the pharmacy

Sources: [6] [8] [13] [10]

Brand-name listings require a second price check

For injectable Wegovy, Zappy’s pricing page lists a $99 monthly care plan plus medication billed separately at approximately $499/month through NovoCare. Injectable Zepbound is listed with the same $99 monthly care charge and a separate medication range of $349–$649/month through Lilly Direct. Those pharmacy channels are material parts of the advertised offers. The figures should not be read as medication-inclusive membership prices, and assistance with prior authorization does not guarantee an insurer will pay.

The homepage also advertises oral Wegovy from $149/month, cash-pay only and restricted to new Novo Nordisk patients. The pricing page separately lists a $99/month care plan for the daily tablet option. The consulted material does not reconcile the starting price with the care fee or establish its duration and full subsequent cost. Likewise, the homepage’s injectable Wegovy starting offer for new Novo Nordisk patients is not adequately reconciled with the approximately $499 NovoCare listing. These are unresolved offer conditions, not a reason to suppress the documented prices.

The brand-name membership includes a form-only initial consultation, a personalized plan, monthly professional check-ins, prescription management, prior-authorization work and customer support. After an insurance denial, Zappy describes self-pay options and guidance exploring an appeal, without promising coverage. Its homepage also advertises FSA/HSA eligibility, but the short statement does not establish individual reimbursement or account rules. A written quote should identify the exact product, pharmacy, care fee, promotional eligibility and later charges.

Sources: [14] [7] [6]

Intake and follow-up: a process, not guaranteed access

Enrollment begins with an online intake covering health history, lifestyle and goals, followed by professional review. Zappy says eligibility depends on health history, goals and existing conditions, and explicitly states that not everyone qualifies. Its terms give a general account-use requirement of age 18 or the legal age of majority. The consulted documentation does not establish uniform laboratory requirements or a complete provider-specific admission protocol. General educational criteria should not be substituted for the service’s actual clinical evaluation.

The help center advertises review and a personalized plan within 24 hours. That is a review target, not a promise of prescription approval or medication arrival. Product pages broadly describe availability in every U.S. state except Hawaii, while the pricing page qualifies availability by location and treatment type. Starter-package exclusions narrow some offers further. Consequently, the broad state claim is not a complete map of which product, pharmacy and package a resident can actually access.

Ongoing care also needs careful reading. The FAQ describes check-ups every four weeks; plan descriptions refer to monthly virtual visits. Four weeks and a calendar month are not identical. Compounded-plan inclusions also name AI-powered assistance available around the clock and premium customer support, which does not establish continuous human clinical availability. As our guide to clinical follow-up explains, a practical question is who evaluates symptoms or treatment concerns between scheduled visits, rather than merely whether a support channel exists.

Sources: [9] [14] [13] [8] [12] [2]

Pharmacy and shipping claims do not fully align

Zappy’s public partner-pharmacy list names Hallandale Pharmacy. Its tirzepatide product page instead says compounded tirzepatide is prepared and dispensed by The Pharmacy Hub, which Zappy describes as a licensed 503A pharmacy. Those statements may describe different arrangements, but the pages do not establish which pharmacy would fulfill every order. Naming a pharmacy is also not independent verification of its licensure, testing or product quality. The responsible dispensing pharmacy should be confirmed for the actual prescription.

Shipment descriptions present another unresolved difference. The help center says multi-month plans are shipped in batches consistent with beyond-use dates, illustrating six months as three separate two-month supplies. The tirzepatide page’s prepaid-plan block instead says all vials ship together. These descriptions cannot safely be treated as interchangeable. A patient paying for a package should obtain its shipment schedule, storage instructions and applicable beyond-use dates rather than infer that prepayment guarantees immediate receipt of the whole package.

Delivery estimates also vary: the FAQ says five to seven business days after the visit, whereas the help center describes typical standard arrival in seven to ten business days. Free standard shipping applies to eligible orders; expedited or overnight delivery is not guaranteed. The FAQ acknowledges tracking-information difficulties. These are estimates, not one reconciled delivery commitment. For an injectable arriving warm or inadequately refrigerated, FDA explicitly advises not using it and contacting the provider or pharmacy. Our shipping-evidence guide explains why dispatch, arrival and product condition are separate questions.

Sources: [11] [10] [8] [6] [12] [1]

Cancellation is the largest documentary conflict

The pricing page advertises no long-term commitment and the ability to pause or cancel anytime. The help center says monthly plans renew automatically, while three-, six- and nine-month plans are paid upfront and require manual renewal. The general terms describe automatic subscription renewal, an email reminder at least 15 days before renewal and cancellation through customer support, effective at the end of the billing cycle. A reminder promise is not the same as a refund right or an immediate end to current obligations.

The dedicated refund policy uses pharmacy-processing milestones. It permits requesting cancellation and a refund before medication has been processed. If the prescription has entered shipping but no tracking number has been assigned, it describes a $30 pharmacy restocking deduction. Once tracking is generated or assigned, the policy says no refund can be issued, although future charges and shipments can be paused on request. The difference between stopping future activity and recovering an existing payment is therefore consequential.

The FAQ adds a separate rule: a 30-day satisfaction guarantee no longer permits immediate termination and a full refund after prescription and shipment, when it says a two-month contract begins from shipment. That conflicts with an uncomplicated reading of cancel-anytime advertising. The general terms’ broader refund restrictions introduce further uncertainty. The public documentation does not resolve which rule governs each plan. Written confirmation should address minimum commitment, renewal, the precise refund cutoff and deductions before payment—not only how to submit cancellation.

Sources: [6] [9] [5] [12] [14]

Turn the remaining gaps into a written record

Zappy’s FAQ directs patients first to customer-service chat in the app and offers solutions@zappyhealth.com as an alternative. Its help center describes Practice Better as the portal for activating a profile and making payments after the initial consultation has been reviewed. These are useful contact and account-management details. They do not establish that customer service can answer clinical questions, that a clinician is continuously available or that every account uses an identical payment workflow.

A focused pre-enrollment message can request one consolidated description of the proposed arrangement: medication name and formulation, route, dispensing pharmacy, included visits, first payment, next payment, shipment schedule and governing cancellation policy. For a brand-name offer, it should also identify the pharmacy channel and any new-patient restriction. For a compounded offer, the clinical conversation should address why that preparation is being proposed for the individual, consistent with FDA’s recommendation concerning needs unmet by an approved drug.

Other unanswered questions deserve plain acknowledgment. The consulted material does not confirm Spanish-language clinical care, translated forms or interpreter access. It does not provide a complete state-by-product availability matrix or independently verified pharmacy-quality records. Portions of the available terms and educational guide were incomplete, limiting conclusions about those documents. These are boundaries of this review, not proof that the services or records do not exist. A responsive, specific written answer would be more informative than another general assurance about personalized care.

Sources: [12] [6] [14] [9] [1]

Questions & answers

Does Zappy’s $99 monthly membership include medication?

Not on the documented brand-name track. That membership covers healthcare services, with the medicine billed separately at the pharmacy. The help center distinguishes it from cash-pay compounded plans, where medication is included. Ask for a product-specific quote because some general pricing language does not clearly maintain that distinction.

Sources: [6] [14]

Can anyone purchase the $159 semaglutide offer?

No. It is advertised for first-time GLP-1 users and requires $477 upfront for three months, rather than separate $159 monthly payments. The package is unavailable in Alabama, Arkansas, California, Kansas, Michigan, Minnesota and Mississippi. Clinical evaluation is still required, and its advertised price does not establish the subsequent renewal price.

Sources: [8] [14]

Which pharmacy would fill a Zappy prescription?

The public pages do not provide one definitive answer for every order. The partner list names Hallandale Pharmacy, while the tirzepatide page identifies The Pharmacy Hub as preparing and dispensing that compounded product. Confirm the pharmacy for the specific prescription and request its contact information before assuming either listing applies.

Sources: [11] [10]

Does 24/7 support mean a clinician is always available?

The documentation does not establish that. The help center specifically includes AI-powered assistance for around-the-clock support, alongside customer support and scheduled professional visits. The FAQ describes check-ups every four weeks. Ask which channel reaches a treating professional, how clinical concerns are escalated and what response interval applies between appointments.

Sources: [8] [12]

Can I cancel after medication has shipped and get a refund?

Do not assume so. The dedicated policy bars refunds once a tracking number is generated or assigned and describes pausing future charges and shipments instead. Separately, the FAQ describes a two-month commitment beginning after prescription and shipment. Because these terms coexist with cancel-anytime advertising, request the applicable plan policy in writing.

Sources: [5] [12] [14]

Do semaglutide or tirzepatide trials establish Zappy’s effectiveness?

No. STEP 1 and SURMOUNT-1 studied specific subcutaneous treatment regimens, not Zappy’s care platform or its compounded preparations. Their findings do not establish outcomes for different formulations, oral routes or individual patients. Zappy’s acknowledgment that its compounded medicines are not FDA approved is relevant, but nonapproval alone does not prove clinical inequivalence.

Sources: [3] [4] [1] [13]

Our assessment

Zappy documents a recognizable telehealth service with online assessment, independent prescribing, medication-inclusive compounded plans and a separate brand-name care membership. Its published prices and contact routes provide useful starting points. The evidence is less settled where product pages, help articles and terms disagree: cancellation commitments, refund boundaries, pharmacy assignment and shipment schedules. Drug-trial findings cannot resolve those operational gaps or establish Zappy-specific outcomes. A reasonable next step is a consolidated written offer naming the product, responsible clinician and pharmacy, full payment structure and controlling cancellation terms. If those answers remain inconsistent, the public documentation is not sufficient to make the proposed arrangement clear.

Visit Zappy Health’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Zappy Health Review: What Its GLP-1 Documentation Establishes—and What It Does Not

At a glance

01Start with the service being documented

02Product evidence is not evidence of Zappy’s results

03What the advertised prices actually include

04Brand-name listings require a second price check

05Intake and follow-up: a process, not guaranteed access

06Pharmacy and shipping claims do not fully align

07Cancellation is the largest documentary conflict

08Turn the remaining gaps into a written record